No funds appropriated under this Act shall be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

D. Where To Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—http://www.cdc.gov. Click on "Funding" then "Grants and Cooperative Agreements."

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from:

Dorimar Rosado, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office Centers for Disease Control and Prevention Room 3000, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: (770) 488–2782, E-mail: dpr7@cdc.gov

For program technical assistance, contact:

Michael St. Louis, MD, Global AIDS Program (GAP), Zimbabwe Country Team, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Zim-CDC AIDS Project Team, 38 Samora Machel Avenue, 2nd Floor, Harare, Zimbabwe, Tel: 263 4 796040, 796048, Fax: 263 4 796032 E-mail: stlouism@zimcdc.co.zw

Dated: July 17, 2001.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01–18284 Filed 7–20–01; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Science and Program Review Subcommittee (SPRS) and the Advisory Committee for Injury Prevention and Control (ACIPC): Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee and committee meetings.

Name: Science and Program Review Subcommittee to ACIPC.

Time and Date: 1 p.m.-4:30 p.m., August 7, 2001.

Place: The Westin Atlanta Airport, 4736 Best Road, College Park, Georgia 30337.

Status: Open: 1 p.m.–1:30 p.m., August 7, 2001; Closed: 1:30 p.m.–4:30 p.m., August 7,

2001. Open to the public, limited only by the space available.

Purpose: The Subcommittee provides advice on the needs, structure, progress and performance of the National Center for Injury Prevention and Control's programs. The Subcommittee provides second-level scientific and programmatic review for applications for research grants, cooperative agreements, and training grants related to injury control and violence prevention, and recommends approval of projects that merit further consideration for funding support. The Subcommittee also advises on priorities for research to be supported by confracts, grants, and cooperative agreements and provides concept review of program proposals and announcements.

Matters to be Discussed: Agenda items include status of program announcements for fiscal year 2002, schedule of monitoring workshops, general announcements and updates, and second-level scientific and programmatic review, discussion, and evaluation of grant applications relating to the support of injury control research centers, individual research grants, and Small Business Innovation Research.

Name: Advisory Committee for Injury Prevention and Control.

Time and Date: 4:45 p.m.-5:45 p.m., August 7, 2001.

Place: The Westin Atlanta Airport, 4736 Best Road, College Park, Georgia 30337.

Status: Open: 4:45 p.m.–5:10 p.m., August 7, 2001; Closed: 5:10 p.m.–5:45 p.m., August 7, 2001.

Purpose: The Committee advises and makes recommendations to the Secretary, the Assistant Secretary for Health, and the Director, CDC, regarding feasible goals for the prevention and control of injury. The Committee makes recommendations regarding policies, strategies, objectives, and priorities, and reviews progress toward injury prevention and control. The Committee provides advice on the appropriate balance of intramural and extramural research, and also provides guidance on the needs, structure, progress and performance of intramural programs, and on extramural scientific program matters. The Committee provides second-level scientific and programmatic review for applications for research grants, cooperative agreements, and training grants related to injury control and violence prevention, and recommends approval of projects that merit further consideration for funding support. The Committee also recommends areas of research to be supported by contracts and cooperative agreements and provides concept review of program proposals and announcements.

Matters to be Discussed: Agenda items include an update from the Director, National Center for Injury Prevention and Control (NCIPC), format proposed for future ACIPC meetings, and consideration, discussion, and vote on SPRS funding recommendations regarding grant applications.

On August 7, 2001, from 1:30 p.m. to 4:30 p.m., the SPRS will convene in closed session, and from 5:10 p.m. to 5:45 p.m., the ACIPC voting members will convene in closed session to discuss and evaluate grant applications. These portions of the meetings

will be closed to the public in accordance with provisions set forth in section 552(c)(4) and (6) title 5 U.S.C., and the Determination of the Deputy Director for Program Management, CDC, pursuant to Pub. L. 92–463

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Mr. Thomas E. Blakeney, Acting Executive Secretary, ACIPC, NCIPC, CDC, 4770 Buford Highway, NE., M/S K61, Atlanta, Georgia 30341–3724, telephone 770/488–1481.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: July 10, 2001.

John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 01–18287 Filed 7–20–01; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organizations, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organizations, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 66 FR 36790–36791, dated July 13, 2001) is amended to modify the mission statement for the Office of the Director, Division of Public Health Systems Development and Research, Public Health Practice Program Office.

Section C–B, Organization and Functions, is hereby amended as follows:

Delete the mission statement for the Office of the Director (CH51), Division of Public Health Systems Development and Research (CH5), Public Health Practice Program Office (CH), and insert the following:

(1) Directs and coordinates the activities of the Division toward their achievement and evaluates results: (2) Develops long-range plans, sets annual objectives, and monitors progress; (3) Provides leadership and management oversight; (4) Serves as a focal point for development State and local public

health capacity, for providing core training to ensure competency of the State and local public health workforce and for assessing State and local health capacity to achieve Year 2010 health objectives; (5) Interacts with public, private, academic, and voluntary sectors of the public health community to foster consensus and adoption of health systems that ensure the capacity for effective response to the National health objectives; (6) Increases the collaboration and fosters the application of resources and capabilities of academic institutions and public health agencies to achieve priority public health goals; (7) Establishes information and knowledge management policies, data systems, and information resources required to support State, local, and Divisional needs; (8) Serves as an advisor to the Director, Public Health Practice Program Officer, on matters related to public health systems, health systems assessment, policy development and assurance, and health system capacity improvement; (9) Coordinates collaborative activities of the Division with other Centers, Institute, and Offices: other Federal agencies; States and local agencies; professional societies; and private health organizations.

Dated: July 13, 2001.

Jeffrey P. Koplan,

Director.

[FR Doc. 01–18211 Filed 7–20–01; 8:45 am] BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N-0006]

Agency Information Collection Activities; Announcement of OMB Approval; New Animal Drug Application, Form FDA 356 V

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "New Animal Drug Application, Form FDA 356 V," has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: In the Federal Register of May 8, 2001 (66 FR 23266), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0032. The approval expires on July 31, 2004. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ ohrms/dockets.

Dated: July 13, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy. [FR Doc. 01–18222 Filed 7–20–01; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D-0084]

Agency Information Collection Activities; Announcement of OMB Approval; Guidance for Industry on Special Protocol Assessment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Guidance for Industry on Special Protocol Assessment" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Karen L. Nelson, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the Federal Register of February 9, 2000 (65 FR 6377), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned

OMB control number 0910–0470. The approval expires on July 31, 2004. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ohrms/dockets.

Dated: July 17, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy. [FR Doc. 01–18344 Filed 7–20–01; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N-0051]

Agency Information Collection Activities; Announcement of OMB Approval; Adverse Event Pilot Program for Medical Devices

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Adverse Event Pilot Program for Medical Devices" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Peggy Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the Federal Register of June 20, 2001 (66 FR 33099), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0471. The approval expires on July 31, 2004. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ ohrms/dockets.

Dated: July 17, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy. [FR Doc. 01–18345 Filed 7–20–01; 8:45 am] BILLING CODE 4160–01–S